The FDA turns to AI to accelerate drug development and approval

23 April 2020

The Artificial Intelligence (AI) and Machine Learning industry is growing at an extraordinary rate, with healthcare professionals increasingly turning to AI to transform the patient experience and quality of care. In the pharmaceutical industry, there is interest in implementing AI-driven solutions to discover new drugs and increase the speed of bringing them to market. Further driving this interest is the US Food and Drug Administraion’s promotion of innovation in the use of AI-based technologies for drug development.

Acceleration of drug development using AI

Drug development and approval is a costly and lengthy process, with much time being dedicated to preliminary research and clinical trials. Indeed, a recent study found that the median research and development cost of bringing a new drug to market is a staggering $985 million.1 AI and machine learning are set to transform the drug discovery process, reducing both the financial cost and time-to-market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK